Welcome to our dedicated page for Spyre Therapeutics SEC filings (Ticker: SYRE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Spyre Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Spyre Therapeutics's regulatory disclosures and financial reporting.
Spyre Therapeutics, Inc. Chief Financial Officer Scott L. Burrows reported option exercises and related share sales. He exercised a stock option for 2,500 shares of common stock at $14.50 per share through a derivative conversion. On the same date, he sold a total of 2,500 shares of common stock in open-market transactions at weighted average prices of $40.56 and $41.66 per share under a pre-established Rule 10b5-1 trading plan adopted on November 10, 2025. After these transactions, he directly held 97,994 shares of common stock, which the filing notes include 67,476 restricted stock units scheduled to vest in equal installments on September 1, 2026 and September 1, 2027, subject to continued employment. The stock option originally covered 404,857 shares, with vesting over several years.
Spyre Therapeutics, Inc.'s Chief Executive Officer, Cameron Turtle, reported selling a total of 15,000 shares of common stock in open-market transactions on March 2, 2026. The sales, executed under a Rule 10b5-1 trading plan adopted on June 20, 2025, were completed in two trades at weighted average prices of $41.73 and $42.49, each reflecting multiple executions within stated price ranges. Following these transactions, the CEO directly holds 642,540 shares of common stock, which includes 130,683 shares scheduled to vest in monthly installments through November 2026, subject to continued service.
Morgan Stanley Smith Barney LLC filed a Form 144 disclosing proposed sales of 60,000 common shares of SYRE, linked to previously exercised stock options dated 06/15/2023. The filing records completed 10b5-1 sales of 15,000 shares on 01/02/2026 and 15,000 shares on 02/02/2026, with proceeds of $460,114.50 and $492,069.00, respectively.
Spyre Therapeutics, Inc. deregistered the unsold securities from its Form S-3 shelf registration by filing Post-Effective Amendment No. 1 on February 27, 2026. The original Registration Statement No. 333-285341 had provided for offerings of up to $500,000,000 in securities and up to $179,059,869 of common stock under a TD Securities sales agreement; the company states it has terminated all offerings and removes any securities still unsold from registration.
Spyre Therapeutics, Inc. files a shelf registration to offer up to $500,000,000 of common stock, preferred stock, debt securities, warrants and/or units pursuant to a base prospectus dated February 19, 2026.
The prospectus supplement states an at-the-market sales agreement with TD Cowen to sell up to $154,059,875 of common stock under the Sales Agreement; Nasdaq last sale price was $36.60 per share on February 18, 2026.
This shelf allows multiple offering methods and will be used for working capital, R&D, potential in-licensing or acquisitions, and general corporate purposes; offering specific terms and proceeds treatment will be set in prospectus supplements.
Spyre Therapeutics reported fourth quarter and full year 2025 results and highlighted progress across its IBD and rheumatic disease pipeline. The company is running two Phase 2 trials: the SKYLINE platform study in ulcerative colitis and the SKYWAY basket trial in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis, with six proof-of-concept readouts planned in 2026.
As of December 31, 2025, Spyre held $756.5 million in cash, cash equivalents, and marketable securities and expects this to fund operations into the second half of 2028. Fourth quarter 2025 R&D expenses were $44.6 million, down from $50.5 million a year earlier, while G&A expenses rose to $12.5 million from $10.8 million.
Other expense in the quarter was $5.4 million, mainly from changes in a contingent value right liability, leading to a quarterly net loss of $62.5 million versus $56.3 million in 2024. For full year 2025, net loss was $155.2 million, compared with $208.0 million in 2024. Spyre also strengthened its balance sheet with an October 2025 underwritten public offering that generated $316.2 million in gross proceeds before $19.8 million in discounts and offering costs.
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company developing long-acting antibody therapies for inflammatory bowel disease and rheumatic diseases. Its core monoclonal antibodies target α4β7 (SPY001), TL1A (SPY002 and SPY072), and IL‑23 (SPY003), including fixed-dose combinations SPY120, SPY130, and SPY230.
The company is running the SKYLINE Phase 2 platform trial in ulcerative colitis and the SKYWAY Phase 2 basket trial of SPY072 in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis, with multiple data readouts expected in 2026 and 2027. Spyre reported approximately $1.1 billion aggregate market value of non‑affiliate equity as of June 30, 2025 and had 78,540,164 common shares outstanding as of February 12, 2026.